| Cyclin-dependent kinase-9 is a therapeutic target in MYC-expressing diffuse large B-cell lymphoma T Hashiguchi, N Bruss, S Best, V Lam, O Danilova, CJ Paiva, J Wolf, ... Molecular cancer therapeutics 18 (9), 1520-1532, 2019 | 52 | 2019 |
| Targeting ubiquitin-activating enzyme induces ER stress–mediated apoptosis in B-cell lymphoma cells S Best, T Hashiguchi, A Kittai, N Bruss, C Paiva, C Okada, T Liu, A Berger, ... Blood advances 3 (1), 51-62, 2019 | 51 | 2019 |
| Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells S Best, V Lam, T Liu, N Bruss, A Kittai, OV Danilova, S Murray, A Berger, ... Leukemia 35 (1), 156-168, 2021 | 34 | 2021 |
| Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma E Thieme, T Liu, N Bruss, C Roleder, V Lam, X Wang, T Nechiporuk, ... Cell death & disease 13 (3), 246, 2022 | 19 | 2022 |
| Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells S Best, T Liu, N Bruss, A Kittai, A Berger, AV Danilov Leukemia & lymphoma, 2019 | 15 | 2019 |
| CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma E Thieme, N Bruss, D Sun, EC Dominguez, D Coleman, T Liu, C Roleder, ... Molecular Cancer 22 (1), 64, 2023 | 13 | 2023 |
| NEDD8-activating enzyme inhibition induces cell cycle arrest and anaphase catastrophe in malignant T-cells AS Kittai, OV Danilova, V Lam, T Liu, N Bruss, S Best, G Fan, AV Danilov Oncotarget 12 (20), 2068, 2021 | 6 | 2021 |
| Pharmacologic inhibition of SUMO-activating enzyme (SAE) with TAK-981 augments interferon signaling and regulates T cell differentiation in ex vivo studies of chronic … V Lam, SR Best, N Bruss, T Liu, TH Rowland, D Huszar, A Danilov Blood 134, 1760, 2019 | 5 | 2019 |
| T cell–intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia V Lam, C Roleder, T Liu, N Bruss, S Best, X Wang, T Phillips, G Shouse, ... Molecular cancer therapeutics 22 (9), 1040-1051, 2023 | 4 | 2023 |
| Transcriptional reprogramming of super-enhancer associated oncogenes following inhibition of cyclin-dependent kinase-9 (CDK9) in aggressive non-Hodgkin lymphoma (NHL) E Thieme, D Sun, GG Sharma, N Bruss, T Liu, DJ Coleman, Z Xia, ... Blood 138, 3493, 2021 | 2 | 2021 |
| Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models E Thieme, V Lam, N Bruss, F Xu, SE Kurtz, JW Tyner, A Danilov, T Liu Blood 136, 29, 2020 | 2 | 2020 |
| Pevonedistat, a small molecule inhibitor of NEDD8-activating enzyme (NAE), induces cell cycle deregulation, anaphase catastrophe, and apoptosis in T-cell lymphoma cells A Kittai, SR Best, T Rowland, N Bruss, C Okada, AV Danilov Blood 132, 1667, 2018 | 1 | 2018 |
| TAK-243, a Small Molecule Inhibitor of Ubiquitin-Activating Enzyme (UAE), Induces ER Stress and Apoptosis in CLL Cells SR Best, T Rowland, C Paiva, N Bruss, SE Spurgeon, A Berger, ... Blood 132, 1867, 2018 | 1 | 2018 |
| Targeting Sumoylation with Subasumstat (TAK-981), a Selective Inhibitor of SUMO-Activating Enzyme (SAE), Induces Mitochondrial Dysfunction in Preclinical Models of Non-Hodgkin … T Liu, V Lam, E Thieme, O Danilova, N Bruss, L Alinari, JW Tyner, ... Blood 140 (Supplement 1), 6016-6017, 2022 | | 2022 |
| Abstract A02: Probing the roles of SUMOylation in B-cell lymphoma cells by using a selective SUMO inhibitor subasumstat (TAK-981) T Liu, V Lam, D Sun, E Thieme, T Nechiporuk, D Bottomly, OV Danilova, ... Blood Cancer Discovery 3 (5_Supplement), A02-A02, 2022 | | 2022 |
| Abstract A06: Strategies to circumvent resistance to cyclin-dependent kinase-9 inhibition (CDK9i) in non-Hodgkin lymphoma (NHL) E Thieme, D Sun, N Bruss, G Sharma, T Liu, D Coleman, T Nechiporuk, ... Blood Cancer Discovery 3 (5_Supplement), A06-A06, 2022 | | 2022 |
| Pharmacologic Inhibition of SUMO-Activating Enzyme Potentiates Interferon Response and T Cell-Mediated Anti-Tumor Immunity in Chronic Lymphocytic Leukemia (CLL) and Lymphoma Models V Lam, X Wang, SR Best, N Bruss, T Liu, O Danilova, T Siddiqi, ... Blood 138, 3719, 2021 | | 2021 |
| Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies SR Best, V Lam, N Bruss, TH Rowland, AS Kittai, T Liu, AJ Berger, ... Blood 134, 4313, 2019 | | 2019 |
| Immunomodulatory Effects of Pevonedistat, a NEDD8-Activating Enzyme (NAE) Inhibitor, in Chronic Lymphocytic Leukemia (CLL) SR Best, A Kittai, T Rowland, N Bruss, SE Spurgeon, A Berger, A Moran, ... Blood 132, 2946, 2018 | | 2018 |
| Impact of Individual Comorbidities on Treatment Outcomes in Chronic Lymphocytic Leukemia MJ Gordon, MC Churnetski, H Alqahtani, XI Rivera, A Kittai, N Bruss, ... Blood 132, 4848, 2018 | | 2018 |
